Printen
Omega-3
vetzuren om langer te leven.*
Onlangs
is een onderzoek geplubiceerd naar de resultaten van meer dan 11.000 trials van
de laatste 40 jaar. Het betrof studies over de effecten van cholesterrol
verlagende middelen zoals statines e.a.en omega3-vetzuren en de kans op
doodgaan, niet alleen door hartproblemen maar door ander e oorzaken.Geen van de
middellen verlaagde deze kans met uitzondering van de statines met 13% en let
wel de omega-3 vetzuren met 23%.
In
the prestigious Archives of Internal Medicine, a review article was published on
the effect of different lipid-lowering agents and diets on your mortality. This
was one of the most extensive meta-analyses ever seen. The researchers reviewed almost
11,000 clinical trials that were done between 1965 and June 2003, comparing
lipid-lowering interventions to placebo or usual care. Of these clinical trials,
97 were randomized, controlled and reported mortality data in such a
scientifically valid way to be used for further analysis. These 97 trials
involved over 275,000 individuals. The studies reviewed the effects of various
lipid-lowering agents such as the statins (Mevacor, Zocor, Pravachol, etc.),
fibrates, bile acid-binding resins, niacin, diet and omega-3 fatty acids. The
meta-analysis showed that the statin drugs lowered overall mortality by 13%. But
even more significantly, the omega-3 fatty acids decreased overall mortality by
23%. They were almost twice as powerful at reducing death as the statins!
Unfortunately, the other drugs studied had little or no effect on mortality.
Effect
of Different Antilipidemic Agents and Diets on Mortality
A
Systematic Review
Marco
Studer, MD; Matthias Briel, MD; Bernd Leimenstoll, MD; Tracy R. Glass, MSc;
Heiner C. Bucher, MD, MPH
Arch
Intern Med. 2005;165:725-730.
Background
Guidelines for the prevention and treatment of hyperlipidemia are often based on
trials using combined clinical end points. Mortality data are the most reliable
data to assess efficacy of interventions. We aimed to assess efficacy and safety
of different lipid-lowering interventions based on mortality data.
Methods
We conducted a systematic search of randomized controlled trials published up to
June 2003, comparing any lipid-lowering intervention with placebo or usual diet
with respect to mortality. Outcome measures were mortality from all, cardiac,
and noncardiovascular causes.
Results
A total of 97 studies met eligibility criteria, with 137 140 individuals in
intervention and 138 976 individuals in control groups. Compared with
control groups, risk ratios for overall mortality were 0.87 for statins (95%
confidence interval [CI], 0.81-0.94), 1.00 for fibrates (95% CI, 0.91-1.11),
0.84 for resins (95% CI, 0.66-1.08), 0.96 for niacin (95% CI, 0.86-1.08), 0.77
for n-3 fatty acids (95% CI, 0.63-0.94), and 0.97 for diet (95% CI, 0.91-1.04).
Compared with control groups, risk ratios for cardiac mortality indicated
benefit from statins (0.78; 95% CI, 0.72-0.84), resins (0.70; 95% CI, 0.50-0.99)
and n-3 fatty acids (0.68; 95% CI, 0.52-0.90). Risk ratios for noncardiovascular
mortality of any intervention indicated no association when compared with
control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI,
1.01-1.27).
Conclusions
Statins and n-3 fatty acids are the most favorable lipid-lowering interventions
with reduced risks of overall and cardiac mortality. Any potential reduction in
cardiac mortality from fibrates is offset by an increased risk of death from
noncardiovascular causes.
Author Affiliations: Basel Institute for Clinical Epidemiology (Drs Studer,
Briel, and Bucher and Ms Glass) and Department of Internal Medicine (Drs Studer
and Leimenstoll), University Hospital Basel, Basel, Switzerland.
( Mei 2005) (Opm. red.: Omega-3 vetzuren vindt u vooral in vette vissoorten zoals; haring, forel, zalm, makreel, paling, zalmforel en sardines)